CVS Caremark Part D Plans Collaborating With Medicare ACOs On Drug Adherence
This article was originally published in The Pink Sheet Daily
Executive Summary
The collaboration could be an important step toward more firmly establishing the value of drug treatment in lowering overall medical spending, a key goal for biopharma manufacturers looking for ways to adapt to new patient care models.
You may also be interested in...
CMS Interested In Part D Plan Collaboration With Medicare ACOs
In a draft version of its annual instructions to Part D plans, CMS says it is seeking feedback from Part D sponsors and other stakeholders on “possible strategies for achieving better coordination” between stand-alone Medicare Part D plans and accountable care organizations to improve pharmacy care.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.